Related Experiment Videos
Biological response modifiers in the treatment of cancer and infectious diseases
1Hamilton Regional Cancer Centre, Ontario Cancer Foundation, Canada.
Cancer Cells (Cold Spring Harbor, N.Y. : 1989)
|June 1, 1991
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1999
The evidence for tamoxifen and chemotherapy as treatment for metastatic melanoma.
European journal of cancer (Oxford, England : 1990)·1998
The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·1998
Lung cancer practice guidelines: lessons learned and issues addressed by the Ontario Lung Cancer Disease Site Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1997
Consensus on the use of neutrophil-stimulating hematopoietic growth factors in clinical practice: an international viewpoint.
International journal of antimicrobial agents·1997
Are quality of life, patient preferences, and costs realistic outcomes for clinical trials?
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·1997
Epithelial cell plasticity in neoplasia.
Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
Uptake of low-density lipoprotein by malignant cells--possible therapeutic applications.
Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
JE/MCP-1: an early-response gene encodes a monocyte-specific cytokine.
Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
A role for cholinesterases in tumorigenesis?
Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
The soluble interleukin-2 receptor as a marker for human neoplasia and immune status.
Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
New directions in cancer therapy based on aberrant expression of glycosphingolipids: anti-adhesion and ortho-signaling therapy.
Cancer cells (Cold Spring Harbor, N.Y. : 1989)·1991
Integrating a Tumor Size-Overall Survival Model Into a Spatial Quantitative Systems Pharmacology Framework for Antibody-Drug Conjugates in Non-Small Cell Lung Cancer.
CPT: pharmacometrics & systems pharmacology·2026
The Future of all-Comers Trials in the Era of Precision Oncology.
Clinical pharmacology and therapeutics·2026
MyoD and Myogenin regulatory cascade is targeted by tumor signals to repress myogenesis in cancer cachexia.
The Biochemical journal·2026
Beyond the cerebrospinal fluid: Preclinical and clinical evidence on central nervous system penetration and functional activity of oral rapamycin (sirolimus).
Journal of Alzheimer's disease : JAD·2026
Conferone: Sources, Anticancer Mechanisms, and Potential in Overcoming Chemoresistance - A Comprehensive Review.
Current pharmaceutical design·2026